Compare AFL & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFL | BDX |
|---|---|---|
| Founded | 1955 | 1897 |
| Country | United States | United States |
| Employees | N/A | 72000 |
| Industry | Accident &Health Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.9B | 49.4B |
| IPO Year | 1994 | 1998 |
| Metric | AFL | BDX |
|---|---|---|
| Price | $116.59 | $181.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $110.18 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 2.10% | ★ 2.89% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.61 | 1.59 |
| Revenue | $17,164,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.69 | $3.02 |
| P/E Ratio | ★ $32.31 | $114.48 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $105.43 | $140.11 |
| 52 Week High | $130.22 | $213.08 |
| Indicator | AFL | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 48.91 |
| Support Level | $114.63 | $175.20 |
| Resistance Level | $118.84 | $192.41 |
| Average True Range (ATR) | 1.64 | 3.88 |
| MACD | 0.28 | -1.25 |
| Stochastic Oscillator | 48.93 | 31.41 |
Aflac Inc offers supplemental health insurance and life insurance in the United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling the majority of its policies directly to consumers at their places of work, and also reaches out to its customers outside of their worksite through digital mediums. The company has two reportable business segments: Aflac Japan, which generates the maximum revenue, and Aflac U.S.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.